Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Down 40.4% in June

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 155,235 shares, a decrease of 40.4% from the June 15th total of 260,360 shares. Based on an average trading volume of 252,050 shares, the days-to-cover ratio is currently 0.6 days. Approximately 5.0% of the company’s stock are sold short.

Valion Bio, Inc. Common Stock Stock Down 3.9%

Valion Bio, Inc. Common Stock stock opened at $0.45 on Thursday. The company’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $0.93. The company has a quick ratio of 3.02, a current ratio of 3.31 and a debt-to-equity ratio of 0.62. The stock has a market cap of $1.44 million, a P/E ratio of -0.07 and a beta of 1.82. Valion Bio, Inc. Common Stock has a twelve month low of $0.40 and a twelve month high of $5.60.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last announced its earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.